A Study To Assess The Long-Term Safety And Tolerability Of TAK-935 (OV935) As Adjunctive Therapy In Patients With Rare Epilepsy

Overview

About this study

The primary purpose of this study is to investigate the long-term safety and tolerability of TAK-935/OV935 as an adjunctive therapy in patients with epileptic seizures.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients must have participated in a previous TAK-935 study and meet one of the following conditions:

  • Successfully completed a TAK-935 clinical study. 
  • In the opinion of the investigator, the patient has the potential to benefit from the administration of TAK-935.

Exclusion Criteria: 

  • Clinically significant disease, that, in the investigator's opinion, precludes study participation.
  • Enrollment in any other clinical trial involving an investigational drug, device, or treatment in the past 6 months (with the exception of an antecedent study involving TAK-935).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Elaine Wirrell, M.D.

Closed for enrollment

Contact information:

Bridget Neja

(507)266-9150

Neja.Bridget@mayo.edu

More information

Publications

Publications are currently not available